Alvotech (ALVO) Net Income towards Common Stockholders (2021 - 2026)
Alvotech (ALVO) posted Net Income towards Common Stockholders of $1.0 million for Q1 2026, down 99.06% on a QoQ basis from $109.7 million in Q4 2025, and down 99.06% year-over-year from $109.7 million in Q1 2025.
Alvotech (ALVO) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
Alvotech's Net Income towards Common Stockholders history runs 6 years deep, the most recent figure standing at $1.0 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 99.06% year-over-year to $1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$165.1 million (up 38.58% YoY) and the FY2025 annual result came in at $109.7 million, up 144.43% from the prior year.
- Net Income towards Common Stockholders was $1.0 million for Q1 2026 at Alvotech, down from $109.7 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $264.7 million in Q2 2022 and bottomed at -$651.1 million in Q4 2023.
- A 5-year average of -$91.4 million and a median of -$246152.0 in 2023 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders slumped 362.17% — and 2025, when it jumped 51566.14%.
- Alvotech's Net Income towards Common Stockholders stood at -$540.7 million in 2022, then retreated by 20.43% to -$651.1 million in 2023, then jumped by 65.69% to -$223.4 million in 2024, then soared by 149.1% to $109.7 million in 2025, then slumped by 99.06% to $1.0 million in 2026.
- Business Quant data shows ALVO's Net Income towards Common Stockholders at $1.0 million in Q1 2026, $109.7 million in Q4 2025, and -$307.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -2.35 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Alvotech | 907.91 Mn | 907.91 Mn | 5.09 Mn | 1.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.03 Mn |
| Dec 31, 2025 | 109.68 Mn |
| Sep 30, 2025 | -307.87 Mn |
| Jun 30, 2025 | 32.04 Mn |
| Mar 31, 2025 | 109.68 Mn |
| Dec 31, 2024 | -223.39 Mn |
| Sep 30, 2024 | -303.58 Mn |
| Jun 30, 2024 | 148.46 Mn |
| Mar 31, 2024 | -213,111.00 |
| Dec 31, 2023 | -651.14 Mn |
| Aug 31, 2023 | -86.85 Mn |
| Jun 30, 2023 | 138.48 Mn |
| Mar 31, 2023 | -246,152.00 |
| Dec 31, 2022 | -540.69 Mn |
| Aug 31, 2022 | -184.47 Mn |
| Jun 30, 2022 | 264.69 Mn |
| Mar 31, 2022 | -58.90 Mn |
| Dec 31, 2021 | 206.23 Mn |
| Sep 30, 2021 | -33.79 Mn |